AI, omics, and systems biology can now help scientists design targeted drugs for cardiovascular disease pathways once thought ...

Phase 2 data on new cardiovascular drugs (milvexian by Bristol and J&J, and asundexian by Bayer) showed solid safety data, but limited efficacy data. Based on the mixed data, we are not making any ...

Animal studies show hope of an effective and safe treatment for the chronic liver condition affecting 25 percent of US adults.

A quiet revolution in care is helping patients with cardiac amyloidosis, a form of heart failure that long stumped doctors. By Simar Bajaj When James Hicks, 75, was diagnosed with heart failure, it ...

June 17 (UPI) --Eli Lilly and Company said Tuesday it will buy out Boston-based Verve Therapeutics Inc. in a billion dollar deal with plans to advance Verve's new line of experimental cardiac health ...